Treatment of the hypertensive patient in 2030

Bhudia, Roshni

doi:10.1038/s41371-020-00437-9

Cited by 5 publications

(4 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Unfortunately, research on new antihypertensive drugs dramatically slowed over the past few years. We agree with Bhudia that the future in the management of hypertensive patients remains uncertain [ 105 ]. However, significant progress is likely to come over the next few years from a combination of education and technology worldwide.…”

Section: Discussionsupporting

confidence: 76%

Advances in the Treatment Strategies in Hypertension: Present and Future

Verdecchia

Cavallini

Angeli

2022

JCDD

View full text Add to dashboard Cite

Hypertension is the most frequent chronic and non-communicable disease all over the world, with about 1.5 billion affected individuals worldwide. Its impact is currently growing, particularly in low-income countries. Even in high-income countries, hypertension remains largely underdiagnosed and undertreated, with consequent low rates of blood pressure (BP) control. Notwithstanding the large number of clinical observational studies and randomized trials over the past four decades, it is sad to note that in the last few years there has been an impressive paucity of innovative studies. Research focused on BP mechanisms and novel antihypertensive drugs is slowing dramatically. The present review discusses some advances in the management of hypertensive patients, and could play a clinical role in the years to come. First, digital/health technology is expected to be increasingly used, although some crucial points remain (development of non-intrusive and clinically validated devices for ambulatory BP measurement, robust storing systems enabling rapid analysis of accrued data, physician-patient interactions, etc.). Second, several areas should be better outlined with regard to BP diagnosis and treatment targets. Third, from a therapeutic standpoint, existing antihypertensive drugs, which are generally effective and well tolerated, should be better used by exploiting available and novel free and fixed combinations. In particular, spironolactone and other mineral-corticoid receptor antagonists should be used more frequently to improve BP control. In particular, some drugs initially developed for conditions different from hypertension including heart failure and diabetes have demonstrated to lower BP significantly and should therefore be considered. Finally, renal artery denervation is another procedure that has proven effective in the management of hypertension.

show abstract

Section: Discussionsupporting

confidence: 76%

Advances in the Treatment Strategies in Hypertension: Present and Future

Verdecchia

Cavallini

Angeli

2022

JCDD

View full text Add to dashboard Cite

show abstract

“…Hypertension was not a treatable disease about half a century ago. However, today, it is a prevalent, noncommunicable chronic disease worldwide and could be inhibited by drugs [ 1 ]. Patients with hypertension had increased possibility of morbidity and mortality when undergoing anesthesia [ 2 ].…”

Section: Introductionmentioning

confidence: 99%

Effect of Thiopental on Ischemic Stroke in Rat Brain in Spontaneously Hypertensive Rats

You

Zhao

Yan

et al. 2022

Applied Bionics and Biomechanics

View full text Add to dashboard Cite

Motivation and Problem Statement. Thiopental is an anesthetic drug related to the condition of controlling the area of neurological contexts. This study is related to the analysis of effectiveness for the condition of thiopental application on spontaneously hypertensive rats. Methodology. We have evaluated the thiopental induction as the anesthetic agent. The hypertensive rats were selected to administer thiopental in the form of anesthesia. The selection and application of hypertensive strokes are related to the derivation of an inducible model to assess the efficacy for analyzing the ischemic stroke parameters which relate to the human body. We used middle cerebral artery occlusion (MCAO) models related to spontaneous hypertension with the area of examining the complications in ischemic stroke. Results and Conclusion. The study focused on the experimental analysis based on the selection of spontaneously hypertensive rats associated with the incidence of ischemic stroke. Application of thiopental has reported the weak functionality and mechanism on the relaxation of neuronal activity in the case of rat brain. The considered population of the spontaneously hypertensive rats is evaluated based on the condition of effectiveness as well as the duration of the medication effects within the rat brain. Involvement of thiopental in the case of ischemic stroke has provided the area of risk development for high rate of death incidences after occurrence of acute ischemic stroke. A complication in the area of defining neuroprotective actions provides difficulty in drawing an appropriate conclusion of the study.

show abstract

“…Unfortunately, research into new antihypertensive drugs has notably slowed down in recent years. In agreement with experts like Bhudia [103] and Verdecchia [11], the future of the management of hypertensive patients remains uncertain. However, significant progress will likely occur in the coming years due partly to the introduction of new biological drugs on the market.…”

Section: Discussionmentioning

confidence: 86%

Genetics of Hypertension: From Monogenic Analysis to GETomics

Zappa,

Golino,

Verdecchia

et al. 2024

JCDD

View full text Add to dashboard Cite

Arterial hypertension is the most frequent cardiovascular risk factor all over the world, and it is one of the leading drivers of the risk of cardiovascular events and death. It is a complex trait influenced by heritable and environmental factors. To date, the World Health Organization estimates that 1.28 billion adults aged 30–79 years worldwide have arterial hypertension (defined by European guidelines as office systolic blood pressure ≥ 140 mmHg or office diastolic blood pressure ≥ 90 mmHg), and 7.1 million die from this disease. The molecular genetic basis of primary arterial hypertension is the subject of intense research and has recently yielded remarkable progress. In this review, we will discuss the genetics of arterial hypertension. Recent studies have identified over 900 independent loci associated with blood pressure regulation across the genome. Comprehending these mechanisms not only could shed light on the pathogenesis of the disease but also hold the potential for assessing the risk of developing arterial hypertension in the future. In addition, these findings may pave the way for novel drug development and personalized therapeutic strategies.

show abstract

Treatment of the hypertensive patient in 2030

Cited by 5 publications

References 8 publications

Advances in the Treatment Strategies in Hypertension: Present and Future

Advances in the Treatment Strategies in Hypertension: Present and Future

Effect of Thiopental on Ischemic Stroke in Rat Brain in Spontaneously Hypertensive Rats

Genetics of Hypertension: From Monogenic Analysis to GETomics

Contact Info

Product

Resources

About